Literature DB >> 1438621

Negative symptoms and the early course of schizophrenia.

J A Husted1, M Beiser, W G Iacono.   

Abstract

To determine the usefulness of including a duration criterion in the definition of "negative" symptoms, the prognostic significance of a longitudinally obtained measure of negative symptoms was compared with a cross-sectionally obtained measure. As predicted, the presence of negative symptoms based on longitudinal observation was associated with most aspects of 18-month course in a group of "first-episode" schizophrenic individuals, whereas cross-sectional levels of negative symptoms were not. The findings suggest that negative symptoms, when operationalized as a trait-like phenomenon, help to portend a poor course of illness.

Entities:  

Mesh:

Year:  1992        PMID: 1438621     DOI: 10.1016/0165-1781(92)90054-7

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  4 in total

1.  Negative symptoms and their association with depressive symptoms in the long-term course of schizophrenia.

Authors:  Wolfram An der Heiden; Anne Leber; Heinz Häfner
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-04-23       Impact factor: 5.270

2.  Diagnosis and six-month stability of negative symptoms in psychotic disorders.

Authors:  S Fennig; E J Bromet; N Galambos; K Putnam
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1996       Impact factor: 5.270

Review 3.  Negative symptoms in schizophrenia: considerations for clinical trials. Working group on negative symptoms in schizophrenia.

Authors:  H J Möller; H M van Praag; B Aufdembrinke; P Bailey; T R Barnes; J Beck; H Bentsen; F X Eich; L Farrow; W W Fleischhacker
Journal:  Psychopharmacology (Berl)       Date:  1994-06       Impact factor: 4.530

4.  Event-related potentials to rare visual targets and negative symptom severity in a transdiagnostic psychiatric sample.

Authors:  Giulia C Salgari; Geoffrey F Potts; Joseph Schmidt; Chi C Chan; Christopher C Spencer; Jeffrey S Bedwell
Journal:  Clin Neurophysiol       Date:  2021-04-09       Impact factor: 4.861

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.